PHARMATEL: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMATEL
Largest movements
- Receivables within one year -€522,585
down €522,585 (-80.0%), from €652,964 to €130,380
of which Other amounts receivable: -€525,050
- Cash -€190,020
down €190,020 (-87.7%), from €216,699 to €26,679
mainly Contributions, distributions and other (-€1.5m)
- Profit (loss) carried forward -€1.0m
down €1.0m (-98.5%), from €1.0m to €15,201
- Other debts +€319,556
up €319,556 (+131.8%), from €242,409 to €561,965
- Financial income +€399,961
up €399,961 (+1455.0%), from €27,488 to €427,450
- Taxes +€2,195
new in 2025: €2,195
- Gross operating margin +€1,507
up €1,507 (+33.3%), from €4,521 to €6,028
- Other operating charges +€148
up €148 (+14.5%), from €1,024 to €1,172
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,346,267 | €1,633,662 | -€712,605 | -30.4% |
| Fixed assets | 21/28 | €1,476,603 | €1,476,603 | = | 0.0% |
| Financial fixed assets | 28 | €1,476,603 | €1,476,603 | = | 0.0% |
| Current assets | 29/58 | €869,663 | €157,059 | -€712,605 | -81.9% |
| Amounts receivable within one year | 40/41 | €652,964 | €130,380 | -€522,585 | -80.0% |
| Trade receivables | 40 | €218 | €2,684 | +€2,466 | +1130.7% |
| Other amounts receivable | 41 | €652,746 | €127,696 | -€525,050 | -80.4% |
| Cash at bank and in hand | 54/58 | €216,699 | €26,679 | -€190,020 | -87.7% |
| Total equity and liabilities | 10/49 | €2,346,267 | €1,633,662 | -€712,605 | -30.4% |
| Equity | 10/15 | €2,103,409 | €1,071,201 | -€1.0m | -49.1% |
| Contributions | 10/11 | €960,000 | €960,000 | = | 0.0% |
| Capital | 10 | €960,000 | €960,000 | = | 0.0% |
| Issued capital | 100 | €960,000 | €960,000 | = | 0.0% |
| Reserves | 13 | €96,000 | €96,000 | = | 0.0% |
| Non-distributable reserves | 130/1 | €96,000 | €96,000 | = | 0.0% |
| Legal reserve | 130 | €96,000 | €96,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €1,047,409 | €15,201 | -€1.0m | -98.5% |
| Amounts payable | 17/49 | €242,858 | €562,461 | +€319,604 | +131.6% |
| Amounts payable within one year | 42/48 | €242,858 | €562,461 | +€319,604 | +131.6% |
| Taxes, remuneration and social security | 45 | €449 | €496 | +€48 | +10.7% |
| Taxes | 450/3 | €449 | €496 | +€48 | +10.7% |
| Other amounts payable | 47/48 | €242,409 | €561,965 | +€319,556 | +131.8% |
| Other operating charges | 640/8 | €1,024 | €1,172 | +€148 | +14.5% |
| Gross operating margin | 9900 | €4,521 | €6,028 | +€1,507 | +33.3% |
| Operating profit (loss) | 9901 | €3,497 | €4,856 | +€1,359 | +38.9% |
| Financial income | 75/76B | €27,488 | €427,450 | +€399,961 | +1455.0% |
| Recurring financial income | 75 | €27,488 | €427,450 | +€399,961 | +1455.0% |
| Financial charges | 65/66B | €390 | €419 | +€29 | +7.4% |
| Recurring financial charges | 65 | €390 | €419 | +€29 | +7.4% |
| Profit (loss) for the period before taxes | 9903 | €30,595 | €431,887 | +€401,292 | +1311.6% |
| Income taxes | 67/77 | - | €2,195 | +€2,195 | |
| Profit (loss) for the period | 9904 | €30,595 | €429,692 | +€399,097 | +1304.5% |
| Profit (loss) for the period to be appropriated | 9905 | €30,595 | €429,692 | +€399,097 | +1304.5% |
Source: filed annual accounts (NBB), financial years ended 31 March 2024 and 31 March 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 11 October 2026 via checked.be.